Year | Citation | Score | |||
---|---|---|---|---|---|
2023 | Powers S, Likhite S, Gadalla KK, Miranda CJ, Huffenberger AJ, Dennys C, Foust KD, Morales P, Pierson CR, Rinaldi F, Perry S, Bolon B, Wein N, Cobb S, Kaspar BK, et al. Novel MeCP2 Gene Therapy is Effective in a Multicenter Study using Two Mouse Models of Rett Syndrome and is Safe in Non-human Primates. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37481701 DOI: 10.1016/j.ymthe.2023.07.013 | 0.471 | |||
2014 | Gadalla KK, Ross PD, Riddell JS, Bailey ME, Cobb SR. Gait analysis in a Mecp2 knockout mouse model of Rett syndrome reveals early-onset and progressive motor deficits. Plos One. 9: e112889. PMID 25392929 DOI: 10.1371/journal.pone.0112889 | 0.46 | |||
2013 | Gadalla KK, Bailey ME, Spike RC, Ross PD, Woodard KT, Kalburgi SN, Bachaboina L, Deng JV, West AE, Samulski RJ, Gray SJ, Cobb SR. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 18-30. PMID 23011033 DOI: 10.1038/Mt.2012.200 | 0.497 | |||
2011 | Gadalla KK, Bailey ME, Cobb SR. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. The Biochemical Journal. 439: 1-14. PMID 21916843 DOI: 10.1042/BJ20110648 | 0.484 | |||
Show low-probability matches. |